Log In
Print this Print this

soraprazan (formerly Remofuscin)

  Manage Alerts
Collapse Summary General Information
Company Katairo GmbH
DescriptionPotassium-competitive acid blocker
Molecular Target H+/K ATPase pump
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat Stargardt's disease
Regulatory Designation EU - Orphan Drug (Treat Stargardt's disease)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today